Cart
sales@molnova.com
Triclopyr 2-butoxyethyl ester
CAS No. 64700-56-7
Triclopyr 2-butoxyethyl ester( —— )
Catalog No. M35821 CAS No. 64700-56-7
Triclopyr 2-butoxyethyl ester (Triclopyr-butotyl) is a bioactive substance. Triclopyr 2-butoxyethyl ester shows toxicity to Apis mellifera.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 65 | In Stock |
|
| 5MG | 48 | In Stock |
|
| 10MG | 71 | In Stock |
|
| 25MG | 122 | In Stock |
|
| 50MG | 179 | In Stock |
|
| 100MG | 267 | In Stock |
|
| 200MG | 401 | In Stock |
|
| 500MG | 663 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTriclopyr 2-butoxyethyl ester
-
NoteResearch use only, not for human use.
-
Brief DescriptionTriclopyr 2-butoxyethyl ester (Triclopyr-butotyl) is a bioactive substance. Triclopyr 2-butoxyethyl ester shows toxicity to Apis mellifera.
-
DescriptionTriclopyr 2-butoxyethyl ester (Triclopyr-butotyl) is a bioactive substance. Triclopyr 2-butoxyethyl ester shows toxicity to Apis mellifera.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number64700-56-7
-
Formula Weight356.63
-
Molecular FormulaC13H16Cl3NO4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCCCOCCOC(=O)COC1=NC(Cl)=C(Cl)C=C1Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
AKOS037652256
AKOS037652256 can be used as a TRPML modulator for the treatment of diseases associated with TRPML activity such as lysosomal accumulation disorders, muscular dystrophy, common age-related neurodegenerative diseases, oxidative stress or reactive oxygen species (ROS)-related diseases and ageing.
-
Dihydrolicoisoflavon...
Dihydrolicoisoflavone A possesses weaker anti-H. pylori activity, it may be useful chemopreventive agents for peptic ulcer or gastric cancer in H. pylori-infected individuals.
-
BV02
BV02 is an inhibitor of 14-3-3 protein-protein interactions and can be used in studies about the treatment of chronic myeloid leukemia. BV02 disrupts hematopoietic cells expressing the IM-resistant T315I mutation and the IM-sensitive wild-type Bcr-Abl.
